Status:
COMPLETED
To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN
Lead Sponsor:
Nanjing University School of Medicine
Collaborating Sponsors:
Sun Yat-sen University
Conditions:
Lupus Nephritis
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
1. To compare the efficacy of FK506 vs intravenous cyclophosphamide pulses in the treatment of class III-IV LN. 2. To compare the safety and tolerability of FK506 vs intravenous cyclophosphamide pulse...
Detailed Description
Corticosteroid combined with cytotoxic drugs has been regarded as the conventional therapy for Class IV Lupus Nephritis (LN), because of its efficacy in improving patients' long term survival. However...
Eligibility Criteria
Inclusion
- Female patients with a diagnosis of Systemic Lupus Erythematosus (SLE) according to the criteria of American Rheumatic Association, 1982 (Appendix 1) aged between 18-65 years, and whose score of SLE-DAI (Disease Active Index, Appendix 2) is greater than 10.
- Patients diagnosed to have class III or IV LN by renal biopsy, according to the WHO classification criteria (1995, Appendix 3) within 3 month and have significant active pathological lesion.
- Patients with a proteinuria ≥ 2g/24h, and an active urine sediment (Hematuria with white cells and casts in urine).
- Patients who signed written informed consent form (patients less than 18 years old with their parents/legal representative's signatures), and have given their consent to follow all study procedures and follow-up.
Exclusion
- Patients who have received treatment of cytotoxic drugs such as CTX, Mycophenolate mofetil (MMF) cyclosporine for more than 1 week within three months, but Azathioprine (AZa) are accepted.
- Patients with serum creatinine \> 3 mg/dl（265μmol/L）.
- Patients with severe infection or central nervous system symptoms.
- Patients who have impaired liver function, with ALT/GPT or AST/GOT twice more than the normal upper limit or who have active hepatitis.
- Patients who have abnormal glucose, with a fasted blood glucose \> 6.2 mmol/L or post meal blood glucose \> 11.2 mmol/L.
- Patients who are pregnant or lactating.
- Patients who are known to be allergic to a macrolide.
- Patients who use Erythromycin, Fluconazole, Ethinylestradiol, Rifampicin, and Carbamazepine.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00302549
Start Date
May 1 2004
End Date
February 1 2006
Last Update
May 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine
Nanjing, Jiangsu, China, 210002